Innocrin Pharmaceuticals, the spanking-new spinout of successful antifungal company Viamet, just raised $8 million according to regulatory filings. The company has taken Viamet’s findings and translated them as a therapy for a tough-to-treat form of prostate cancer. This past October, Viamet withdrew its plans to go public in favor of raising $60 million in private equity […]
Drug discovery and development firm Viamet Pharmaceuticals has named a new top financial executive as the company readies two clinical stage compounds for potential drug partners. Dr. Richard Katz was appointed to the newly created position of chief business and financial officer. His responsibilities will include overseeing commercial and financial operations for the Durham, North […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Viamet Pharmaceuticals has hired a Novartis (NYSE:NVS) executive to become the company’s first chief medical officer. Dr. Marc Rudoltz will oversee development of Durham, North Carolina-based Viamet’s oncology and infectious disease therapies. “We are excited to have Dr. Rudoltz join the Viamet team,” Viamet CEO Robert Schotzinger said in a statement. “He will play a […]